. 2023 Sep 28;37(5):355–366. doi: 10.7555/JBR.37.20230022

Table 4. IC ₅₀s of cisplatin when it was administrated in combination with GEM and GEM-ZZQ in H1975-OR cell lines .

GEM/ GEM-ZZQ (nmol/L)	Combined GEM (μg/mL) ^a	Combined GEM-ZZQ (μg/mL) ^a	Fold change
Student's t-test was used to test the differences between the two groups. ^* P < 0.05. ^aData are presented as mean ± standard deviation, n = 3. Fold change = IC ₅₀ (GEM-ZZQ)/IC ₅₀ (GEM). Bold text indicates a better synergistic effect compare to the group Comb GEM. GEM-ZZQ indicates the prodrug with an H ₂O ₂-sensitive thiazolidinone moiety at the 4th amino group of GEM. Abbreviation: GEM, gemcitabine; OR, osimertinib-resistant.
0	0.730±0.055	0.741±0.049	1.015
6.25 ^*	0.642±0.020	0.405±0.029	0.631
12.50 ^*	0.437±0.029	0.369±0.018	0.844
25.00 ^*	0.175±0.017	0.287±0.011	1.640
50.00 ^*	0.076±0.007	0.119±0.009	1.566

Table 4. IC 50s of cisplatin when it was administrated in combination with GEM and GEM-ZZQ in H1975-OR cell lines .